U.S. FDA nod for Lupin's generic of Janssen Pharma's blood thinner tablets

Drugmaker Lupin has received U.S. Food and Drug Administration (U.S. FDA) approval for Rivaroxaban Tablets USP, 10 mg, 15 mg, and 20 mg, its generic version of Janssen Pharmaceuticals' blood thinner tablet Xarelto.
The product will be manufactured at its Aurangabad facility. The approved product had an estimated annual sales of $8,052 million in the U.S., Lupin said citing IQVIA MAT March 2025 numbers. Rivaroxaban Tablets USP are indicated to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation and for treatment of deep vein thrombosis as well as pulmonary embolism, it said.
Rivaroxaban Tablets are bioequivalent to Xarelto, which Jannsen said is a blood thinner to treat and help prevent blood clots related to certain conditions involving the heart and blood vessels.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Hindu

a day ago

• The Hindu

Granules unit in Hyderabad, one of the largest globally for paracetamol API, under U.S. FDA scanner

Generic drugmaker Granules India's active pharmaceutical ingredients (API) manufacturing facility in Bonthapally, Hyderabad, has been issued an observation by the U.S. Food and Drug Administration (U.S. FDA). The Bonthapally facility is one of the world's largest single-site paracetamol API manufacturing plants by volume. Along with paracetamol APIs, the company has established Metformin and Guaifenesin API manufacturing plants in the same facility, Granules India said in an intimation to the stock exchanges on Friday. The U.S. FDA had inspected the facility, located in Sangareddy district, from June 16-20 and issued Form 483 with one observation. The company said it will respond to the observation within the stipulated time.

The Hindu

2 days ago

• The Hindu

U.S. FDA issues 7 observations to Natco Pharma's formulations unit in Hyderabad

The U.S. Food and Drug Administration (U.S. FDA) has issued seven observations to Natco Pharma's formulations facility in Kothur, Hyderabad. The facility was inspected by the U.S. FDA from June 9-19. On conclusion, the company received seven observations in Form-483, Natco Pharma said on Thursday. The company said it is confident of addressing the observations within the stipulated timeline. 'The company remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally,' Natco Pharma said. The U.S. FDA had in April 2024 issued a warning letter to the facility while raising quality concerns. The action followed an inspection and issue of eight observations in October 2023 by the regulator. The company then said the move may result in delay or withholding of pending product approvals from the site. The facility is for oral solid dosages, including cytotoxic orals; cytotoxic injectables; and pre filled syringes. The focus product categories are oncology, gastroenterology, central nervous system and cardiology. EOM

Time of India

2 days ago

• Time of India

US FDA approves Gilead's twice-yearly injection for HIV prevention

By Deena Beasley and Julie Steenhuysen Los Angeles: The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir , a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of contracting the deadly virus. Investors and AIDS activists had been eagerly awaiting the regulatory decision for the drug seen as convenient enough to help end the 44-year-old HIV epidemic. It will be sold under the brand name Yeztugo in the U.S. at a list price of $28,218 a year. Lenacapavir, part of a class of drugs known as capsid inhibitors, proved nearly 100% effective at preventing HIV in large trials last year, raising new hope of interrupting transmission of the virus that infects 1.3 million people a year. Yeztugo "will only be as effective as it is accessible and affordable," Kevin Robert Frost, CEO of the Foundation for AIDS Research, said in a statement, calling on Gilead and the U.S. government to make sure people who want lenacapavir can get it. Gilead said it is working to secure health insurer coverage. It said it will provide co-pay assistance for eligible insured people, and the drug may be available free of charge for some under its program for the uninsured. Medications to prevent HIV, known as pre-exposure prophylaxis, or PrEP, are widely available. But most are daily pills, including low-cost generic versions of Gilead's older drug Truvada, that require strict adherence to be effective. Gilead said Yeztugo is priced in line with other branded drugs. "This is a milestone moment," said Gilead Chief Executive Daniel O'Day of the approval. "We believe that lenacapavir is the most important tool we have yet to bend the arc of the epidemic and move this epidemic into the history books," O'Day said. Availability of a twice-yearly HIV prevention tool is "a huge advance," that could help change the course of the epidemic, Dr. Raphael Landovitz, director of the UCLA Center for Clinical AIDS Research & Education, said in an email. But he said the product's high launch price "is almost certainly going to complicate payor coverage and access." Gilead has plans for a rapid launch in the United States as well as a wider rollout of the drug in collaboration with global partners. Gilead's chief commercial officer, Johanna Mercier, said the company's "end game" is to normalize PrEP usage, both in the United States and other countries, including low-income African nations where the virus is most prevalent. Citi Research analyst Geoff Meacham said he expects Yeztugo's launch to be slow and steady, reaching annual sales of $2.8 billion by 2030. Mercier said she expects around 75% of U.S. insurers, including government health plans, will cover lenacapavir for PrEP within about six months, with the number rising to 90% within 12 months of launch. The drug is currently sold as a treatment in the U.S. under the brand name Sunlenca for patients with advanced disease that has become resistant to other drugs. PEPFAR CUTS In December, the President's Emergency Plan for AIDS Relief (PEPFAR) under then-President Joe Biden signed an agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to provide the treatment to as many as 2 million people for three years if it won U.S. regulatory approval for prevention. That would allow for unprecedented early access to a state-of-the-art treatment, as six generic drugmakers that have licensed the product from Gilead gear up for production of low-cost versions in 120 resource-limited countries. AIDS activists have viewed the drug as a way to significantly slow the epidemic, but cuts to PEPFAR by the Trump administration have raised concerns about the U.S. government's commitment to the rollout. O'Day acknowledged that the changes have been "challenging," but said the company has continued to have discussions with both the Global Fund and PEPFAR. "I believe that there will be sources of funding for this, and that these organizations will prioritize this type of prevention," he said.